650-888-7302
Home  |  About  |  Photos  |  Contact  |  Privacy

Drew Watson Ph.D.

Advancing Personalized Medicine

 

Biosketch

Key Points

Education

Dr. Watson holds a Bachelor of Science degree in Statistics from California State University, East Bay, a Master of Science degree in Computational Statistics from Stanford University, an M.B.A. from Golden Gate University and a Ph.D. in Biostatistics from UCLA.

Experience

Dr. Watson is currently Senior Vice President of Biostatistics¸ Data Management and Medical Operations for Genomic Health, Inc. During the past 20 years, Dr. Watson has served in various Executive positions ranging from CEO, General Manager and various VP roles.

Expertise

Dr. Watson is an influential leader in the fields of biostatistics, personalized medicine, molecular diagnostics, quality and business management. Drew is a scientific and business advisor to multiple companies and has numerous publications.

Drew Watson, Ph.D., MBA

Biosketch

Dr. Watson is an influential leader in the fields of biostatistics, personalized medicine, molecular diagnostics, and business management. He was instrumental in the development of Oncotype DX®– a clinically-validated diagnostic test that has revolutionized personal medicine by quantifying the likelihood of disease recurrence in women with early-stage breast cancer and providing individualized estimates of chemotherapy benefit as well as development of viral load polymerase chain reaction (PCR)and branched DNA (bDNA) based molecular assays in HIV patients. Dr. Watson has served as Senior Vice President of Biostatistics¸ Data Management and Medical Operations of Genomic Health, Inc., since February 2003. From June 2001 to December 2002, Dr. Watson served as Chief Executive Officer of Novation Biosciences, Inc. From March 1997 to April 2001, Dr. Watson served in various roles at Incyte Genomics, Inc., including General Manager of Incyte's Microarray Division, Vice President Corporate Development, and Vice President of Computational Biology. From June 1994 to March 1997, Dr. Watson was Director of Non-Clinical Biostatistics for Chiron Corporation.

Prior to his work in biological research, Dr. Watson spent 15 years in statistical and management consulting under the guidance of Dr. W. Edwards Deming – considered to be the Father of the Japanese Industrial Revolution – and Dr. Perry Gluckman – a renowned statistician and quality management consultant. Under the guidance of the late Dr. Deming and Dr. Gluckman, Dr. Watson worked with executives from electronic and manufacturing companies including Intel, Hewlett-Packard, NEC, Applied Materials, Armstrong World Industries and Dow Chemicals to improve the quality and productivity of their organizations.

Dr. Watson has published extensively in the area of oncology research, genomics and personalized medicine, and is an inventor of a number of key patents related to genomics, algorithm development, and molecular diagnostics. Dr. Watson holds a Bachelor of Science degree in Statistics from California State University, East Bay, a Master of Science degree in Computational Statistics from Stanford University, an M.B.A. from Golden Gate University and a Ph.D. in Biostatistics from UCLA.


Scientific Advisory Roles

In addition to his role as SVP of Biostatistics, Data Management and Medical Operations at Genomic Health, Dr. Watson is a scientific and business advisor to the following companies.

  • ALT NAME

    Telome Health

    Drew is a Scientific Advisor to Telome Health, Inc. - founded by Nobel Laureate Elizabeth Blackburn dedicated to leveraging the predictive power of telomere science and telomere mechanism of aging to assess health status, disease risk, and responses to specific therapies.

    Keep reading...

  • ALT NAME

    Bullet Biotechnology

    Drew is a Scientific Advisor to Bullet Biotechnology - an innovative biotech company developing a personalized therapeutic vaccine for B-cell lymphomas based on Stanford technology. The vaccine stimulates the patient's own immune system to attack their cancer.

    Keep reading...

  • ALT NAME

    Organ-I

    Drew is a Scientific Advisor to Organ-I, Inc. - utilizing genomic technologies to develop non-invasive tests to monitor and predict organ health. Organ-I’s technology was developed from more than 10 years of research at Stanford University resulting in over 130 medical journal publications.

    Keep reading...